{
    "clinical_study": {
        "@rank": "112484", 
        "acronym": "GFM-EXVD-AZA", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Experimental", 
                "description": "Patients will be included in 2 groups according to the ferritin level at time of inclusion.\nPatients with the ferritin level >300ng/ml and < 1000ng/ml, will be included in Group 1.\n5 patients in each cohort: Cohort 1: Deferasirox: 5mg/kg/d Cohort 2: Deferasirox: 10mg/kg/d Cohort 3: Deferasirox: 15mg/kg/d"
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Experimental", 
                "description": "Patients will be included in 2 groups according to the ferritin level at time of inclusion.\nPatients with the ferritin level > 1000ng/ml, will be included in Group 2.\n5 patients in each cohort: Cohort 1: Deferasirox: 10mg/kg/d Cohort 2: Deferasirox: 15mg/kg/d Cohort 3: Deferasirox: 20mg/kg/d"
            }
        ], 
        "brief_summary": {
            "textblock": "Determinate safety and response rate of the association Deferasirox -Vitamine D -\n      Azacitidine in treatment of high risk MDS\n\n      Deferasirox Exjade:\n\n      The dose of Deferasirox will be assigned according to the ferritin level. Dose escalation is\n      scheduled during the phase I, with 5 additional patients per group.\n\n      The maximal tolerated dose of Deferasirox will be required for the phase II of the study.\n\n      The first dose will be assigned according to the ferritin level of the patient at time of\n      inclusion:\n\n      5 mg/kg/d if the ferritin is >300ng/ml and < 1000ng/ml in Group 1 10 mg/kg/d if the ferritin\n      is  \u22651000ng/ml) in Group 2\n\n      Group 1 : Ferritin  300 to 1000ng /ml:\n\n        -  cohort 1 : 5 mg/kg/d\n\n        -  cohort 2 : 10mg/kg/d\n\n        -  cohort 3 : 15 mg/kg/d\n\n      Group 2 : Ferritin > 1000ng /ml:\n\n        -  cohort 1 : 10 mg/kg/d\n\n        -  cohort 2 : 15mg/kg/d\n\n        -  cohort 3 : 20 mg/kg/d\n\n           5 patients will be treated by cohort. In absence of toxicity (extra-hematological\n           toxicity grade 3 or 4 or hematological grade 4), 5 additional patients will be included\n           in the next cohort.\n\n      Deferasirox will be administrated once daily during all the study period. Uvedose will be\n      administrated once weekly during all the study period (100.000 UI P.O).\n\n      Azacitidine will be administrated sc at 75 mg/m\u00b2/d, during 7 days, J1 to J7 of each\n      cycles(One cycle is 28 days)\n\n      During phase I and II, Deferasirox will always be associated with Vitamin D and Azacitidine\n\n      Patients will be received 6 cycles of treatment (except if progression, unacceptable\n      toxicity or withdrawn of patients occured) After 3 and 6 cycles, an evaluation will be done\n      to evaluate the efficacy of the treatment.\n\n      No dose modification of deferasirox will be done after 3 cycles of treatment except in case\n      of progression). After 6 cycles, patients with CR, PR, marrow CR or HI will be treated with\n      the same dose of Deferasirox until progression ."
        }, 
        "brief_title": "A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDS", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "MDS", 
        "detailed_description": {
            "textblock": "Deferasirox will be administrated once daily in the morning on an empty stomach, 30 minutes\n      before meal.\n\n      Deferasirox will be stopped if the ferritin level is under 100 ng/ml,and could be restarted\n      is the ferritin level increase to 200 ng/ml\n\n      Uvedose dose could be adjusted according to the phosphocalcic metabolism parameters and the\n      plasma Vitamin D3 level."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  High risk MDS, according to OMS classification\n\n          -  High risk CMML (WBC < 13 G/L)\n\n          -  AREBT of the FAB classification with less than 30% of blastes\n\n          -  IPSS>=1.5 (int-2 and high risk)\n\n          -  Age >=18y\n\n          -  Performance status<=2 (ECOG)\n\n          -  Bilirubin and transaminase < 1.5 x ULN\n\n          -  Normal renal function\n\n          -  Patient not eligible for Allogeneic stem cell transplant\n\n          -  Male and female patients must use an effective contraceptive method during the study\n             and for a minimum of 3 months after study treatment.\n\n          -  Agree the need for the use of a condom if engaged in sexual activity with a pregnant\n             woman or a woman of childbearing potential. during the entire period of treatment,\n             even if disruption of treatment and during 3 months after end of treatment\n\n          -  Male patient: Agree not to conceive during treatment and study drug therapy\n             (including doses interruptions) and for 3 months after the end of the study drug\n             therapy\n\n          -  Agree not to donate semen during study drug therapy and for one week after end of\n             study drug therapy.\n\n          -  Agree  to learn about the procedures for preservation of sperm,before starting\n             treatment\n\n          -  Patient be able to adhere to the study visit schedule and other protocol requirements\n\n        Exclusion Criteria:\n\n          -  Active infection or uncontrolled disease\n\n          -  Use of cytotoxic chemotherapeutic agents or experimental agents(agents that are not\n             commercially available) for the treatment of MDS within 28 days. In case of used of\n             cytotoxic chemotherapeutic agents or hypomethylating agent a wash out of 3 mont is\n             required.\n\n          -  Active Cancer or Cancer within one year before inclusion\n\n          -  Previous calcic urinary lithiasis\n\n          -  Previous hyperparathyroid primitive disease or uncontrolled\n\n          -  Hypercalcemia, hyperphosphoremia, hypervitaminosis D\n\n          -  Patient already include in another experimental study\n\n          -  Active infection by HIV, hepatite B or C\n\n          -  Pregnant or lactating females\n\n          -  Patient not able (medical/psychiatric) to understand and sign the written consent\n\n          -  Patients with a ferritin level less than 300ng/ml\n\n          -  Patient eligible for an Allogeneic stem cell transplant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01718366", 
            "org_study_id": "GFM-EXVD-AZA-2011-005623-41"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group 1", 
                "Group 2"
            ], 
            "intervention_name": "Deferasirox, Vitamin D and Azacitidine", 
            "intervention_type": "Drug", 
            "other_name": [
                "Exjade", 
                "Uvedose", 
                "Vidaza"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Azacitidine", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins", 
                "Deferasirox"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 17, 2014", 
        "location": [
            {
                "contact": {
                    "email": "abanos@ch-cotebasque.fr", 
                    "last_name": "Anne Banos, MD", 
                    "phone": "033559443832"
                }, 
                "facility": {
                    "address": {
                        "city": "Bayonne", 
                        "country": "France", 
                        "zip": "64100"
                    }, 
                    "name": "Centre Hospitalier de La Cote Basque"
                }, 
                "investigator": {
                    "last_name": "Anne Banos, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "thorsten.braun@avc.aphp.fr", 
                    "last_name": "Thorsten Braun, MD", 
                    "phone": "33148957051"
                }, 
                "facility": {
                    "address": {
                        "city": "Bobigny", 
                        "country": "France", 
                        "zip": "93009"
                    }, 
                    "name": "H\u00f4pital Avicenne"
                }, 
                "investigator": {
                    "last_name": "Thorsten Braun, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rose.christian@ghicl.net", 
                    "last_name": "Christian Rose, MD", 
                    "phone": "33320874532"
                }, 
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59020"
                    }, 
                    "name": "H\u00f4pital Saint Vincent de Paul"
                }, 
                "investigator": {
                    "last_name": "Christian Rose, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13009"
                    }, 
                    "name": "Institut Paoli Calmettes"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nancy", 
                        "country": "France", 
                        "zip": "54511"
                    }, 
                    "name": "CHU Brabois"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France", 
                        "zip": "44093"
                    }, 
                    "name": "CHU Nantes"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "francois.dreyfus@cch.aphp.fr", 
                    "last_name": "Fran\u00e7ois Dreyfus, MD", 
                    "phone": "33158411996"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75679"
                    }, 
                    "name": "H\u00f4pital cochin"
                }, 
                "investigator": {
                    "last_name": "Fran\u00e7ois Dreyfus, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "pierre.fenaux@sls.aphp.fr", 
                    "last_name": "Pierre Fenaux, MD", 
                    "phone": "033170207022"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75010"
                    }, 
                    "name": "H\u00f4pital saint Louis"
                }, 
                "investigator": {
                    "last_name": "Pierre Fenaux, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "olivier.hermine@nck.aphp.fr", 
                    "last_name": "Olivier Hermine, MD", 
                    "phone": "33144495283"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75743"
                    }, 
                    "name": "H\u00f4pital Necker"
                }, 
                "investigator": [
                    {
                        "last_name": "Olivier Hermine, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Felipe Suarez, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase I-II Study of Association of Deferasirox, Vitamin D and Azacytidine as Treatment of High Risk MDS (IPSS Int-2 and High)", 
        "overall_contact": {
            "email": "felipe.suarez@nck.aphp.fr", 
            "last_name": "Felipe Suarez, MD", 
            "phone": "033144495286"
        }, 
        "overall_contact_backup": {
            "email": "benedicte.samey@avc.aphp.fr", 
            "last_name": "Benedicte SAMEY, CRA", 
            "phone": "033148955590"
        }, 
        "overall_official": [
            {
                "affiliation": "Necker Hospital (Paris)", 
                "last_name": "Olivier Hermine, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Saint Louis Hospital (Paris)", 
                "last_name": "Pierre Fenaux, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Necker Hospital (Paris)", 
                "last_name": "Felipe Suarez, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "patient will be evaluable after at least one cycle. Treatment will be administrated during 6 month and responders will be treated until progression or death", 
            "measure": "To determine the maximal tolerated dose(MTD", 
            "safety_issue": "Yes", 
            "time_frame": "6 month of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01718366"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Groupe Francophone des Myelodysplasies", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Groupe Francophone des Myelodysplasies", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}